Evidence map›Paper›PMID 37573528›Full record

ArticleJournal of pharmacokinetics and pharmacodynamics2024

Training the next generation of pharmacometric modelers: a multisector perspective.

Peter L Bonate, Jeffrey S Barrett, Sihem Ait-Oudhia, Richard Brundage, Brian Corrigan, Stephen Duffull, Marc Gastonguay, Mats O Karlsson, Shinichi Kijima, Andreas Krause and 9 more

Erratum issuedAbstract readLetter
PubMed Publisher
In one paragraph

Article in Journal of pharmacokinetics and pharmacodynamics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Peter L BonateAstellas, Northbrook, IL, USA. peter.bonate@astellas.com.
Jeffrey S BarrettAridhia Bioinformatics, Glasgow, Scotland, UK.
Sihem Ait-OudhiaMerck & Co., Inc, Kenilworth, NJ, USA.
Richard BrundageMetrum Research Group, University of Minnesota, Minneapolis, MN, USA.
Brian CorriganPfizer, Groton, CT, USA.
Stephen DuffullCertara, Princeton, NJ, USA.
Marc GastonguayMetrum Research Group, Tariffville, CT, USA.
Mats O KarlssonDepartment of Pharmacy, Uppsala University, Uppsala, Sweden.
Shinichi KijimaOffice of New Drug V, Pharmaceuticals and Medical Devices Agency (PMDA), Tokyo, Japan.
Andreas KrauseIdorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Mark LovernCertara, Princeton, NJ, USA.
Matthew M RiggsMetrum Research Group, Tariffville, CT, USA.
Michael NeelyChildren's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
Daniele OuelletJanssen (Johnson & Johnson), Spring House, PA, USA.
Elodie L PlanPharmetheus, Uppsala, Sweden.
Gauri G RaoUNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
Joseph StandingGreat Ormond Street Institute of Child Health, University College London, London, UK.
Justin WilkinsOccams Coöperatie U.A., Amstelveen, The Netherlands.
Hao ZhuFood and Drug Administration, Silver Springs, MD, USA.

Funding

Medical Research Council MR/M008665/1
6 · The paper itself

Abstract

The current demand for pharmacometricians outmatches the supply provided by academic institutions and considerable investments are made to develop the competencies of these scientists on-the-job. Even with the observed increase in academic programs related to pharmacometrics, this need is unlikely to change in the foreseeable future, as the demand and scope of pharmacometrics applications keep expanding. Further, the field of pharmacometrics is changing. The field largely started when Lewis Sheiner and Stuart Beal published their seminal papers on population pharmacokinetics in the late 1970's and early 1980's and has continued to grow in impact and use since its inception. Physiological-based pharmacokinetics and systems pharmacology have grown rapidly in scope and impact in the last decade and machine learning is just on the horizon. While all these methodologies are categorized as pharmacometrics, no one person can be an expert in everything. So how do you train future pharmacometricians? Leading experts in academia, industry, contract research organizations, clinical medicine, and regulatory gave their opinions on how to best train future pharmacometricians. Their opinions were collected and synthesized to create some general recommendations.

Indexed as

PharmacologyCareer ChoiceHumansPharmacokineticsEducationModeling and simulationPharmacometrics

Identifiers

PMID37573528

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.